Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Esthesioneuroblastoma: full-pipeline trial registry
4 of 4 indexed Esthesioneuroblastoma trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Esthesioneuroblastoma: 4 US clinical trials tracked, 4 recruiting.
Esthesioneuroblastoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Arizona, running 1 of these trials.
Enrollment posture brief
Registry condition esthesioneuroblastoma
OPEN 4 | RECR 100% | LATE 1 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Esthesioneuroblastoma lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Esthesioneuroblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Esthesioneuroblastoma is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Natural History Study of Children and Adults With Olfactory Neuroblastoma
National Cancer Institute (NCI)
NCT04755205
Long-Term Longitudinal QoL in Patients Undergoing EEA
Ohio State University
NCT04087902
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Weill Medical College of Cornell University
NCT04081701
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06814496
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Esthesioneuroblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Esthesioneuroblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Esthesioneuroblastoma page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Esthesioneuroblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Arizona sponsors the most Esthesioneuroblastoma trials on record, review their full trial history before evaluating a specific study. See University of Arizona's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Esthesioneuroblastoma condition card totals 4 registered trials; most-linked intervention Ga68-DOTATATE-PET/MRI; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.